MUMBAI, India, Oct. 26 -- Intellectual Property India has published a patent application (202611112235 A) filed by Dr. Navneet Verma; Shubham Sharma; Dr Prithu Pathak; Md Iftekhar Ahmad; Dr. Mohan Verma; Dr. Pankaj Kumar Sharma; Dr. Pawan Kumar Kare; Dr. Deepak Jain; Chinmaya Mahapatra; Reshma H Pakali; Salman Ahmad Khan; Miss Dilsarbanu Ilyasbhai Gohil; and Nayyar Parvez on September 18, 2026, for Nano-Lipid Carriers (nlcs) Vs Solid Lipid Nanoparticles (slns): Comparative Study For Drug Stability And Bioavailability.
Inventors include Dr. Navneet Verma; Shubham Sharma; Dr Prithu Pathak; Md Iftekhar Ahmad; Dr. Mohan Verma; Dr. Pankaj Kumar Sharma; Dr. Pawan Kumar Kare; Dr. Deepak Jain; Chinmaya Mahapatra; Reshma H Pakali; Salman Ahmad Khan; Miss Dilsarbanu Ilyasbhai Gohil; and Nayyar Parvez.
The application for the patent was published on October 23, 2026, under issue no. 43/2026.
Abstract: The present invention relates to an optimized nanostructured lipid carrier (NLC) formulation comprising a binary lipid matrix of glyceryl monostearate and oleic acid at a 70:30 ratio, stabilized with poloxamer 188 and polysorbate 80, encapsulating a model BCS Class II drug and produced by hot high-pressure homogenization. Comparative evaluation against conventional solid lipid nanoparticles (SLNs) prepared under identical conditions demonstrates superior NLC performance. The NLC exhibits a particle size of 132.6 nanometres, encapsulation efficiency of 93.7 percent, and drug loading of 8.6 percent, compared with 168.4 nanometres, 76.3 percent, and 5.8 percent, respectively, for SLNs. The disordered lipid matrix reduces crystallinity from 82.6 to 54.3 percent, minimizing drug expulsion and enabling 91.8 percent drug retention at six months versus 64.8 percent for SLNs. In vivo oral pharmacokinetic evaluation demonstrates 3.85-fold and 1.63-fold bioavailability enhancement over drug suspension and SLNs, respectively, establishing NLCs as the preferred lipid nanoparticulate platform.
Disclaimer: Curated by HT Syndication.
